Malley L A, Slone T W, Van Pelt C, Elliott G S, Ross P E, Stadler J C, Kennedy G L
E. I. DuPont de Nemours and Company, Haskell Laboratory for Toxicology and Industrial Medicine, Newark, Delaware 19714.
Fundam Appl Toxicol. 1994 Aug;23(2):268-79. doi: 10.1006/faat.1994.1105.
The potential chronic toxicity and oncogenicity of dimethyl-formamide (DMF) was evaluated by exposing male and female rats and mice to 0, 25, 100, or 400 ppm DMF for 6 hr/day, 5 days/week for 18 months (mice) or 2 years (rats). Clinical pathology was evaluated at 3, 6, 12, 18, and 24 (rats only) months. An interim euthanasia for rats occurred at 12 months and hepatic cell proliferation in rats and mice was examined at 2 weeks, 3 months, and 12 months. No compound-related effects on clinical observations or survival were observed. Body weights of rats exposed to 100 (males only) and 400 ppm were reduced. Conversely, body weights were increased in 400 ppm mice. No hematologic changes were observed in either species. Serum sorbitol dehydrogenase activity was increased in rats exposed to 100 or 400 ppm. There were no compound-related effects on the estrous cycle of rats or mice at any concentration. Compound-related morphological changes were observed only in the liver. In rats, exposure to 100 and 400 ppm produced increased relative liver weights, centrilobular hepatocellular hypertrophy, lipofuscin/hemosiderin accumulation in Kupffer cells, and centrilobular single cell necrosis (400 ppm only). In mice, increased liver weights (100 ppm males, 400 ppm both sexes), centrilobular hepatocellular hypertrophy, accumulation of lipofuscin/hemosiderin in Kupffer cells, and centrilobular single cell necrosis were observed in all exposure groups. These observations occurred in a dose-response fashion and were minimal at 25 ppm. No increase in hepatic cell proliferation was seen in mice or female rats. Slightly higher proliferation was seen in male rats exposed to 400 ppm at 2 weeks and 3 months but not at 12 months. Dimethylformamide was not oncogenic under these experimental conditions in either the rat or mouse.
通过让雄性和雌性大鼠及小鼠每天暴露于0、25、100或400 ppm二甲基甲酰胺(DMF)中,每周5天,持续18个月(小鼠)或2年(大鼠),来评估DMF的潜在慢性毒性和致癌性。在3、6、12、18和24个月(仅大鼠)时评估临床病理学。大鼠在12个月时进行中期安乐死,并在2周、3个月和12个月时检查大鼠和小鼠的肝细胞增殖情况。未观察到与化合物相关的对临床观察或存活的影响。暴露于100 ppm(仅雄性)和400 ppm的大鼠体重减轻。相反,400 ppm小鼠的体重增加。两种物种均未观察到血液学变化。暴露于100或400 ppm的大鼠血清山梨醇脱氢酶活性增加。在任何浓度下,均未观察到与化合物相关的对大鼠或小鼠发情周期的影响。仅在肝脏中观察到与化合物相关的形态学变化。在大鼠中,暴露于100和400 ppm会导致相对肝脏重量增加、小叶中心肝细胞肥大、库普弗细胞中脂褐素/含铁血黄素积累以及小叶中心单细胞坏死(仅400 ppm)。在小鼠中,所有暴露组均观察到肝脏重量增加(100 ppm雄性、400 ppm两性)、小叶中心肝细胞肥大、库普弗细胞中脂褐素/含铁血黄素积累以及小叶中心单细胞坏死。这些观察结果呈剂量反应关系,在25 ppm时最小。在小鼠或雌性大鼠中未观察到肝细胞增殖增加。在2周和3个月时,暴露于400 ppm的雄性大鼠肝细胞增殖略有增加,但在12个月时未增加。在这些实验条件下,二甲基甲酰胺对大鼠或小鼠均无致癌性。